Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Pulses in Neuroendocrine Cell Hyperplasia of Infancy
NCT06471556Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Primary completion
- Feb 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylprednisolone injection in Neuroendocrine Cell Hyperplasia, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of children still requiring oxygen therapy at Month 18. Started Jun 2025; status: recruiting.
02
Drugs
methylprednisolone injection
03
Conditions
Neuroendocrine Cell Hyperplasia
Beyond the preview
Go deeper on NCT06471556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471556.